Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.97)
# 1,706
Out of 4,429 analysts
628
Total ratings
50.6%
Success rate
5.4%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintained: Buy | $155 | $123.76 | +25.24% | 47 | Jun 16, 2026 | |
| PFE Pfizer | Maintained: Hold | $27 | $25.21 | +7.10% | 59 | Jun 6, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $985 → $1,230 | $1,098.57 | +11.96% | 99 | May 1, 2026 | |
| AMGN Amgen | Maintained: Hold | $350 | $337.60 | +3.67% | 48 | Apr 30, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintained: Buy | $800 | $609.94 | +31.16% | 51 | Apr 29, 2026 | |
| ABBV AbbVie | Maintained: Buy | $240 | $216.49 | +10.86% | 47 | Apr 29, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $45 → $54 | $54.00 | - | 35 | Apr 8, 2026 | |
| MRK Merck & Co. | Maintained: Hold | $120 | $113.87 | +5.38% | 44 | Mar 29, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | n/a | $78.78 | - | 18 | Feb 25, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $485 → $590 | $451.63 | +30.64% | 9 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $51.44 | n/a | 2 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $196.58 | n/a | 45 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $55.15 | n/a | 24 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.168 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.49 | n/a | 14 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $1.26 | n/a | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.75 | n/a | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $158.29 | n/a | 29 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.662173 | n/a | 9 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $160 | $222.72 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $95.80 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | €81.08 | $132.90 | n/a | 1 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $82 → $86 | $98.22 | n/a | 4 | Jul 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $94 | $536.59 | n/a | 1 | May 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $4 | $2.40 | n/a | 2 | Feb 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $2.8 | $9.63 | n/a | 2 | Jan 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $13 | $1.20 | n/a | 2 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $75 | $3.15 | n/a | 3 | May 16, 2018 |
Gilead Sciences
Jun 16, 2026
Maintained: Buy
Price Target: $155
Current: $123.76
Upside: +25.24%
Pfizer
Jun 6, 2026
Maintained: Hold
Price Target: $27
Current: $25.21
Upside: +7.10%
Eli Lilly and Company
May 1, 2026
Maintained: Buy
Price Target: $985 → $1,230
Current: $1,098.57
Upside: +11.96%
Amgen
Apr 30, 2026
Maintained: Hold
Price Target: $350
Current: $337.60
Upside: +3.67%
Regeneron Pharmaceuticals
Apr 29, 2026
Maintained: Buy
Price Target: $800
Current: $609.94
Upside: +31.16%
AbbVie
Apr 29, 2026
Maintained: Buy
Price Target: $240
Current: $216.49
Upside: +10.86%
Bristol-Myers Squibb Company
Apr 8, 2026
Maintained: Hold
Price Target: $45 → $54
Current: $54.00
Upside: -
Merck & Co.
Mar 29, 2026
Maintained: Hold
Price Target: $120
Current: $113.87
Upside: +5.38%
Cytokinetics
Feb 25, 2026
Maintained: Buy
Price Target: n/a
Current: $78.78
Upside: -
Vertex Pharmaceuticals
Feb 13, 2026
Maintained: Buy
Price Target: $485 → $590
Current: $451.63
Upside: +30.64%
Jun 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $51.44
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $196.58
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $55.15
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $0.168
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $14.49
Upside: n/a
Nov 8, 2024
Rated: Buy
Price Target: $9
Current: $1.26
Upside: n/a
Nov 7, 2024
Maintained: Buy
Price Target: $12
Current: $1.75
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $160
Current: $158.29
Upside: n/a
Aug 14, 2024
Maintained: Buy
Price Target: $3
Current: $0.662173
Upside: n/a
Jan 11, 2023
Rated: Hold
Price Target: $160
Current: $222.72
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $95.80
Upside: n/a
Feb 27, 2020
Initiated Coverage: Buy
Price Target: €81.08
Current: $132.90
Upside: n/a
Jul 31, 2019
Maintained: Hold
Price Target: $82 → $86
Current: $98.22
Upside: n/a
May 17, 2019
Upgraded: Hold
Price Target: $94
Current: $536.59
Upside: n/a
Feb 1, 2019
Downgraded: Hold
Price Target: $16 → $4
Current: $2.40
Upside: n/a
Jan 11, 2019
Maintained: Hold
Price Target: $6 → $2.8
Current: $9.63
Upside: n/a
Nov 12, 2018
Maintained: Buy
Price Target: $18 → $13
Current: $1.20
Upside: n/a
May 16, 2018
Maintained: Buy
Price Target: $90 → $75
Current: $3.15
Upside: n/a